[1] JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2] SIEGEL R,NAISHADHAM D,JEMAL A.Cancer statistics,2012[J].CA Cancer J Clin,2012,62(1):10-29.
[3] 郝捷,陈万青.2012中国肿瘤登记年报[M].军事医学科学出版社,2012:193-195.
[4] 刘宁,陈明,陈恕求.P504S/AMACR在前列腺癌患者血清中的表达及其意义[J].现代医学,2010,38(3):266-268.
[5] LEROY B E,NORTHRUP N.Prostate cancer in dogs:comparative and clinical aspects[J].Vet J,2009,180(2):149-162.
[6] 崔林,关志忱.种植性雄激素非依赖型前列腺癌动物模型的建立[J].中华泌尿外科杂志,2006,27(11):39-41.
[7] 赵林,姜永光,马杰,等.不同前列腺癌细胞系及其皮下肿瘤上皮间质转化特性鉴定[J].中华男科学杂志,2011,17(4):314-317.
[8] HARA T,MIYAZAKI J,ARAKI H,et al.Novel mutations of androgen receptor A possible mechanism of bicalutamide withdrawal syndrome[J].Cancer Res,2003,63(1):149-153.
[9] 王金秋,李志,何丹,等.SCID小鼠原位接种LNCaP前列腺癌模型的建立[J].北京农业职业学院学报,2012,26(5):19-22.
[10] BOBEK V,HOFFMAN R M,KOLOSTOVA K.Site-specific cytomorphology of disseminated PC-3 prostate cancer cells visualized in vivo with fluorescent proteins[J].Diagn Cytopathol,2012,41(5):413-417.
[11] 王元天,孙颖浩,邱镇,等.人类前列腺癌裸鼠原位移植模型的建立[J].中华泌尿外科杂志,2005,26(3):208-209.
[12] Van WEERDEN W M,ROMIJN J C.Use of nude mouse xenograft models in prostate cancer research[J].Prostate,2000,43(4):263-271.
[13] WANG Y,REVELO M P,SUDILOVSKY D,et al.Development and characterization of efficient xenograft models for benign and malignant human prostate tissue[J].Prostate,2005,64(2):149-159.
[14] 孙宏斌.肾包膜下种植建立人前列腺癌异种移植动物模型[J].中华医学杂志,2010,90(30):2136-2139.
[15] TSINGOTJIDOU A S,ZOTALIS G,JACKSON K R,et al.Development of an animal model for prostate cancer cell metastasis to adult human bone[J].Anticancer Res,2001,21(2A):971-978.
[16] SHEVRIN D H,KUKREJA S C,GHOSH L,et al.Development of skeletal metastasis by human prostate cancer in athymic nude mice[J].Clin Exp Metastasis,1988,6(5):401-409.
[17] ANGELUCCI A,GRAVINA G L,RUCCI N,et al.Evaluation of metastatic potential in prostate carcinoma:an in vivo model[J].Int J Oncol,2004,25(6):1713.
[18] TENNANT T R,KIM H,SOKOLOFF M,et al.The dunning model[J].Prostate,2000,43(4):295-302.
[19] FISHER J L,SCHMITT J F,HOWARD M L,et al.An in vivo model of prostate carcinoma growth and invasion in bone[J].Cell Ttissue Res,2002,307(3):337-345.
[20] ANDERSEN K F,DIVILOV V,KOZIOROWSKI J,et al.Antilipolytic drug boosts glucose metabolism in prostate cancer[J].Nucl Med Biol,2013,40(4):524-528.
[21] KORSTEN H,ZIEL-van der MADE A,MA X,et al.Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model[J].PLoS One,2009,4(5):e5662.
[22] SQUIRE J A,PARK P C,YOSHIMOTO M,et al.Prostate cancer as a model system for genetic diversity in tumors[J].Adv Cancer Res,2011,112:183-216.
[23] GINGRICH J R,BARRIOS R J,MORTON R A,et al.Metastatic prostate cancer in a transgenic mouse[J].Cancer Res,1996,56(18):4096-4102.
[24] JORCYK C.The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer:ductal epithelial cell targeting with multistage progression to carcinoma[J].Oncogene,2000,19(8):1020-1027.
[25] GUPTA S,HASTAK K,AHMAD N,et al.Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols[J].Proc Natl Acad Sci,2001,98(18):10350-10355.
[26] PAULUS M J,GLEASON S S,KENNEL S J,et al.High resolution X-ray computed tomography:an emerging tool for small animal cancer research[J].Neoplasia (New York,NY),2000,2(1-2):62-78.
[27] BERGER F,LEE Y P,LOENING A M,et al.Whole-body skeletal imaging in mice utilizing microPET:optimization of reproducibility and applications in animal models of bone disease[J].Eur J Nucl Med Mol Imaging,2002,29(9):1225-1236.
[28] YAMAMOTO N,TSUCHIYA H,HOFFMAN R M.Tumor imaging with multicolor fluorescent protein expression[J].Int J Clin Oncol,2011,16(2):84-91.
[29] KOLOSTOVA K,PINTEROVA D,HOFFMAN R M,et al.Circulating human prostate cancer cells from an Orthotopic mouse model rapidly captured by immunomagnetic beads and imaged by GFP expression[J].Anticancer Res,2011,31:1535-1540.
[30] 崔明星,詹新立,刘会江,等.人前列腺癌PC-3细胞的荧光标记及其脊椎转移动物模型的建立[J].南方医科大学学报,2013,33(2):243-248.
[31] 武国军,王福利,李晓武,等.转基因小鼠前列腺癌及转移的三维超声微成像[J].实用医学杂志,2009,25(3):354-356.
[32] SCHIMMOLLER F,ZAYZAFOON M,CHUNG L W K,et al.Cabozantinib (XL184),a dual MET-VEGFR2 inhibitor,blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone[J].Mol Cancer Ther,2011,10(5):233-252.
[33] WINKELMANN C T,FIGUEROA S D,SIECKMAN G L,et al.Non-invasive MicroCT imaging characterization and in vivo targeting of BB2 receptor expression of a PC-3 bone metastasis model[J].Mol Imaging Biol,2012,14(6):667-675. |
